In contrast, ibrutinib partially blocks TLR-signaling (30) to inhibit early IL10 gene expression (Figures 5E, F), preventing amplification of TLR-signaling and markedly decreasing the activation state of CLL cells (Figure 6). Here, IL10 is linked to B-cell chronic lymphocytic leukemia.